Search tips
Search criteria 


Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2005 September; 64(9): 1326–1330.
Published online 2005 February 11. doi:  10.1136/ard.2004.031393
PMCID: PMC1755647

Lamivudine is not effective in primary Sjögren's syndrome


Background: Retroviral infection has been implicated in the pathogenesis of primary Sjögren's syndrome.

Objective: To examine the efficacy of the reverse transcriptase inhibitor lamivudine in patients with this syndrome.

Methods: 16 patients with primary Sjögren's syndrome were randomised to receive either lamivudine 150 mg twice daily or placebo for three months. Measures of lacrimal and salivary function, including minor salivary gland biopsies, were obtained before and after treatment.

Results: Treatment with lamivudine did not result in significant improvement in the primary outcome measure of unstimulated whole salivary flow or other secondary measures, including minor salivary gland biopsy focus scores.

Conclusion: Lamivudine is not effective in patients with primary Sjögren's syndrome, suggesting either that a retroviral aetiology is not present or that it may be important only in early disease.

Full Text

The Full Text of this article is available as a PDF (75K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hedfors E, Lindahl G. Variation of MHC class I and II antigen expression in relation to lymphocytic infiltrates and interferon-gamma positive cells. J Rheumatol. 1990 Jun;17(6):743–750. [PubMed]
  • Fox RI, Bumol T, Fantozzi R, Bone R, Schreiber R. Expression of histocompatibility antigen HLA-DR by salivary gland epithelial cells in Sjögren's syndrome. Arthritis Rheum. 1986 Sep;29(9):1105–1111. [PubMed]
  • Lindahl G, Hedfors E, Klareskog L, Forsum U. Epithelial HLA-DR expression and T lymphocyte subsets in salivary glands in Sjögren's syndrome. Clin Exp Immunol. 1985 Sep;61(3):475–482. [PubMed]
  • Adamson TC, 3rd, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol. 1983 Jan;130(1):203–208. [PubMed]
  • Zumla A, Mathur M, Stewart J, Wilkinson L, Isenberg D. T cell receptor expression in Sjögren's syndrome. Ann Rheum Dis. 1991 Oct;50(10):691–693. [PMC free article] [PubMed]
  • Anaya Juan-Manuel, Correa Paula A, Mantilla Ruben D, Arcos-Burgos Mauricio. TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjögren's syndrome. Semin Arthritis Rheum. 2002 Jun;31(6):396–405. [PubMed]
  • Gottenberg Jacques-Eric, Busson Marc, Loiseau Pascale, Cohen-Solal Julien, Lepage Virginia, Charron Dominique, Sibilia Jean, Mariette Xavier. In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003 Aug;48(8):2240–2245. [PubMed]
  • Guggenbuhl P, Jean S, Jego P, Grosbois B, Chalès G, Semana G, Lancien G, Veillard E, Pawlotsky Y, Perdriger A. Primary Sjögren's syndrome: role of the HLA-DRB1*0301-*1501 heterozygotes. J Rheumatol. 1998 May;25(5):900–905. [PubMed]
  • Hay EM, Thomas E, Pal B, Hajeer A, Chambers H, Silman AJ. Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis. 1998 Jan;57(1):20–24. [PMC free article] [PubMed]
  • Kassan SS. Immunogenetics of Sjögren's syndrome. Ann Med Interne (Paris) 1998 Feb;149(1):45–48. [PubMed]
  • Panchovska M, Sheitanov Y, Martinova F. Locus DR in primary Sjögren's syndrome. Bratisl Lek Listy. 2001;102(8):382–382. [PubMed]
  • Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T, Nishinarita S, Hosokawa Y, Horie T, Obara T. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome. Am J Med. 1992 Feb;92(2):134–140. [PubMed]
  • Tapinos NI, Polihronis M, Tzioufas AG, Skopouli FN. Immunopathology of Sjögren's syndrome. Ann Med Interne (Paris) 1998 Feb;149(1):17–24. [PubMed]
  • Yamamoto Kazuhiko. Pathogenesis of Sjögren's syndrome. Autoimmun Rev. 2003 Jan;2(1):13–18. [PubMed]
  • Sasaki M, Nakamura S, Ohyama Y, Shinohara M, Ezaki I, Hara H, Kadena T, Kishihara K, Yamamoto K, Nomoto K, et al. Accumulation of common T cell clonotypes in the salivary glands of patients with human T lymphotropic virus type I-associated and idiopathic Sjögren's syndrome. J Immunol. 2000 Mar 1;164(5):2823–2831. [PubMed]
  • Matsumoto I, Tsubota K, Satake Y, Kita Y, Matsumura R, Murata H, Namekawa T, Nishioka K, Iwamoto I, Saitoh Y, et al. Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome. J Clin Invest. 1996 Apr 15;97(8):1969–1977. [PMC free article] [PubMed]
  • Sumida T, Matsumoto I, Maeda T, Nishioka K. T-cell receptor in Sjögren's syndrome. Br J Rheumatol. 1997 Jun;36(6):622–629. [PubMed]
  • Couderc LJ, D'Agay MF, Danon F, Harzic M, Brocheriou C, Clauvel JP. Sicca complex and infection with human immunodeficiency virus. Arch Intern Med. 1987 May;147(5):898–901. [PubMed]
  • Vernant JC, Buisson G, Magdeleine J, De Thore J, Jouannelle A, Neisson-Vernant C, Monplaisir N. T-lymphocyte alveolitis, tropical spastic paresis, and Sjögren syndrome. Lancet. 1988 Jan 23;1(8578):177–177. [PubMed]
  • Eguchi K, Matsuoka N, Ida H, Nakashima M, Sakai M, Sakito S, Kawakami A, Terada K, Shimada H, Kawabe Y, et al. Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis. 1992 Jun;51(6):769–776. [PMC free article] [PubMed]
  • Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H, Yamashita I, Iwata K, Tsuji Y, Nagataki S, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome. Lancet. 1994 Oct 22;344(8930):1116–1119. [PubMed]
  • Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi K, Takatsuki K. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood. 1996 Oct 15;88(8):3065–3073. [PubMed]
  • Talal N, Dauphinée MJ, Dang H, Alexander SS, Hart DJ, Garry RF. Detection of serum antibodies to retroviral proteins in patients with primary Sjögren's syndrome (autoimmune exocrinopathy). Arthritis Rheum. 1990 Jun;33(6):774–781. [PubMed]
  • Yamano S, Renard JN, Mizuno F, Narita Y, Uchida Y, Higashiyama H, Sakurai H, Saito I. Retrovirus in salivary glands from patients with Sjögren's syndrome. J Clin Pathol. 1997 Mar;50(3):223–230. [PMC free article] [PubMed]
  • Garry RF, Fermin CD, Hart DJ, Alexander SS, Donehower LA, Luo-Zhang H. Detection of a human intracisternal A-type retroviral particle antigenically related to HIV. Science. 1990 Nov 23;250(4984):1127–1129. [PubMed]
  • Mariette X, Agbalika F, Daniel MT, Bisson M, Lagrange P, Brouet JC, Morinet F. Detection of human T lymphotropic virus type I tax gene in salivary gland epithelium from two patients with Sjögren's syndrome. Arthritis Rheum. 1993 Oct;36(10):1423–1428. [PubMed]
  • Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice. Nature. 1989 Sep 7;341(6237):72–74. [PubMed]
  • Steinfeld SD, Demols P, Van Vooren JP, Cogan E, Appelboom T. Zidovudine in primary Sjögren's syndrome. Rheumatology (Oxford) 1999 Sep;38(9):814–817. [PubMed]
  • Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993 Mar;36(3):340–347. [PubMed]
  • Cummins Martin J, Papas Athena, Kammer Gary M, Fox Philip C. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003 Aug 15;49(4):585–593. [PubMed]
  • Atkinson JC, Travis WD, Pillemer SR, Bermudez D, Wolff A, Fox PC. Major salivary gland function in primary Sjögren's syndrome and its relationship to clinical features. J Rheumatol. 1990 Mar;17(3):318–322. [PubMed]
  • Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol. 1996 Sep-Oct;14(5):555–558. [PubMed]
  • Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren's syndrome. Proposed criteria for classification. Arthritis Rheum. 1986 May;29(5):577–585. [PubMed]
  • Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum. 1984 Feb;27(2):147–156. [PubMed]
  • Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974 Feb;37(2):217–229. [PubMed]
  • Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol. 1999 Jun;52(6):487–497. [PubMed]
  • Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000 Jun 22;342(25):1887–1892. [PMC free article] [PubMed]
  • Kruize AA, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993 May;52(5):360–364. [PMC free article] [PubMed]
  • Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999 Apr;58(4):253–256. [PMC free article] [PubMed]
  • Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996 Jun;5 (Suppl 1):S31–S36. [PubMed]
  • Manoussakis MN, Moutsopoulos HM. Antimalarials in Sjögren's syndrome--the Greek experience. Lupus. 1996 Jun;5 (Suppl 1):S28–S30. [PubMed]
  • Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med. 1988 Oct 14;85(4A):62–67. [PubMed]
  • Drosos AA, Skopouli FN, Galanopoulou VK, Kitridou RC, Moutsopoulos HM. Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year. Scand J Rheumatol Suppl. 1986;61:246–249. [PubMed]
  • Dalavanga YA, Detrick B, Hooks JJ, Drosos AA, Moutsopoulos HM. Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjögren's syndrome. Ann Rheum Dis. 1987 Feb;46(2):89–92. [PMC free article] [PubMed]
  • Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern Med. 1999 Dec;38(12):938–943. [PubMed]
  • Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Fletcher D, Valdez IH, Kurrasch RH, Delapenha R, Jackson W. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol. 1993 Mar-Apr;11(2):149–156. [PubMed]
  • Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 2001 Oct;44(10):2371–2375. [PubMed]
  • Mariette Xavier, Ravaud Philippe, Steinfeld Serge, Baron Gabriel, Goetz Joelle, Hachulla Eric, Combe Bernard, Puéchal Xavier, Pennec Yvon, Sauvezie Bernard, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004 Apr;50(4):1270–1276. [PubMed]
  • Fox RI, Saito I. Criteria for diagnosis of Sjögren's syndrome. Rheum Dis Clin North Am. 1994 May;20(2):391–407. [PubMed]
  • Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554–558. [PMC free article] [PubMed]
  • Papas AS, Fernandez MM, Castano RA, Gallagher SC, Trivedi M, Shrotriya RC. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögrens syndrome. Adv Exp Med Biol. 1998;438:973–978. [PubMed]
  • Petrone Dianne, Condemi John J, Fife Rose, Gluck Oscar, Cohen Stanley, Dalgin Paul. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002 Mar;46(3):748–754. [PubMed]
  • Fife Rose S, Chase Walter F, Dore Robin K, Wiesenhutter Craig W, Lockhart Peter B, Tindall Elizabeth, Suen James Y. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002 Jun 10;162(11):1293–1300. [PubMed]
  • Asmussen KH, Bowman SJ. Outcome measures in Sjögren's syndrome. Rheumatology (Oxford) 2001 Oct;40(10):1085–1088. [PubMed]
  • Bowman SJ, Pillemer S, Jonsson R, Asmussen K, Vitali C, Manthorpe R, Sutcliffe N. Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology (Oxford) 2001 Oct;40(10):1180–1188. [PubMed]
  • Pflugfelder SC, Tseng SC, Sanabria O, Kell H, Garcia CG, Felix C, Feuer W, Reis BL. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998 Jan;17(1):38–56. [PubMed]
  • Schein OD, Tielsch JM, Munõz B, Bandeen-Roche K, West S. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology. 1997 Sep;104(9):1395–1401. [PubMed]
  • Tiplady B, Jackson SH, Maskrey VM, Swift CG. Validity and sensitivity of visual analogue scales in young and older healthy subjects. Age Ageing. 1998 Jan;27(1):63–66. [PubMed]
  • Humphreys-Beher MG, Brayer J, Yamachika S, Peck AB, Jonsson R. An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Scand J Immunol. 1999 Jan;49(1):7–10. [PubMed]
  • Jonsson R, Kroneld U, Bäckman K, Magnusson B, Tarkowski A. Progression of sialadenitis in Sjögren's syndrome. Br J Rheumatol. 1993 Jul;32(7):578–581. [PubMed]
  • Leroy JP, Pennec YL, Soulier C, Berthelot JM, Letoux G, Youinou P. Follow up study of labial salivary gland lesions in primary Sjögren's syndrome. Ann Rheum Dis. 1992 Jun;51(6):777–780. [PMC free article] [PubMed]
  • Rostron Jocelyne, Rogers Simon, Longman Lesley, Kaney Sue, Field E Anne. Health-related quality of life in patients with primary Sjögren's syndrome and xerostomia: a comparative study. Gerodontology. 2002 Jul;19(1):53–59. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group